StreetAlpha.app
Home › Stocks › MIRM

Mirum Pharmaceuticals, Inc. (MIRM)

Healthcare
Members
LATEST PRICE

Mirum develops and sells medicines for rare liver and other rare diseases, based in Foster City, California. MIRM reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (9 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.

Prices, price targets and earnings estimates for MIRM are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is MIRM in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 3
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
Strong Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
9firms
9 Buy0 Hold0 Sell
Each firm's latest rating on MIRM in the past 90 days
Average 12-month target
Price targets for MIRMThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
StifelMaintained
Oct 15Buy
Evercore ISI GroupMaintained
Oct 13Buy
Morgan StanleyTarget raised
Oct 13Buy
CitigroupTarget raised
Oct 12Buy
HC Wainwright & Co.Target raised
Oct 12Buy
DateFirmActionRatingPrice target
Oct 15StifelMaintainedBuy
Oct 13Evercore ISI GroupMaintainedBuy
Oct 13Morgan StanleyTarget raisedBuy
Oct 12CitigroupTarget raisedBuy
Oct 12HC Wainwright & Co.Target raisedBuy
Loading…

Whale Options Flow

90D

No whale options trades in MIRM in the last 90 days.

Loading…

Dark Pool

30D
Prints
2
Notional
Members
Largest print
Members
Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MIRM is in one of them and how their past MIRM trades turned out.

See how it works→ View all auto pilots→
MIRM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MIRM in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company based in Foster City, California, that develops and sells medicines for rare diseases, mainly rare liver conditions. Its approved products are Livmarli, used to treat severe itching in certain rare cholestatic liver diseases, and Cholbam and Ctexli, used for bile acid disorders and a rare brain and tendon condition. It sells these medicines mainly in the United States and through partners in other countries, and it is developing treatments for other rare liver diseases and a rare genetic neurological disorder. Its customers include patients, physicians and specialty pharmacies.

Headquarters
Foster City, CA
Founded
2018
Summary based on the company’s 2026 annual report (10-K) ↗